RE:You just never know.The aggressive M&A strategy that Pfizer has just completed which could be supercharged by the introduction of a 10% tax on repatriated profits is very sobering, especially at a time when PLI is just about to start climbing the revenue ladder with the approval of Pg and to differentiate 4050 from other standard of care drugs, notably in the IPF field.
As Barcode mentioned the other day, Roche paid $8.2B for pirfenidone and Shire $4.2 for C1-INH. I suggest a takeover bid between these two sums could be attractive to a lot of shareholders and obviously represent a massively huge value proposition for the company acquiring PLI. Again, this underscores the need for management to sign deals on 4050 in order to build walls to prevent a successful takeover bid from occuring. I would hate to see what would happen if PLI had to go to the equity markets hat in hand once again. It would not be a pretty sight.